Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
Status:
Recruiting
Trial end date:
2026-04-29
Target enrollment:
Participant gender:
Summary
The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety
of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
after failure of no less than second-line chemotherapy or targeted therapy